Search for a trial

A Phase II, randomized, double blind, parallel group,46 weeks dose-finding study of BI 456906 administered once weekly subcutaneously compared with placebo in patients with obesity or overweight

The overall purpose of this trial is to assess the efficacy on weight loss and maintenance, and tolerability of four different doses of BI 456906 compared to placebo in patients with obesity or overweight (BMI >= 27kg/m2), without type 1 or…

Open-label, randomised, 4 parallel-group, Phase I clinical trial to investigate BI 456906 occupancy of Glucagon receptors in liver and Glucagon-like Peptide 1 receptors in pancreas in comparison with semaglutide after administration of radiolabeled tracer in male and female subjects with obesity using PET and MRI

This study has been transitioned to CTIS with ID 2024-515417-17-00 check the CTIS register for the current data. The main objective of this trial is to investigate glucagon receptor occupancy of BI 456906 in the liver with PET imaging using the…